Laboratory-based surveillance of extensively drug-resistant tuberculosis, China

Emerging Infectious Diseases

Volumn 17, Issue 3, 2011, Pages 495-497

  Deng, Yunfeng ^a   Wang, Yan ^a   Wang, Junling ^a   Jing, Hui ^a   Yu, Chunbao ^a   Wang, Haiying ^a   Liu, Zhimin ^a   Graviss, Edward A ^b   Ma, Xin ^a,b  

^a SHANDONG PROVINCIAL CHEST HOSPITAL   (China)

^b HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOSALICYLIC ACID; CAPREOMYCIN; CIPROFLOXACIN; ETHAMBUTOL; ISONIAZID; LEVOFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; STREPTOMYCIN;

ARTICLE; BACTERIUM CULTURE; BACTERIUM ISOLATE; CHINA; DISEASE SURVEILLANCE; DRUG SENSITIVITY; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; HUMAN; LABORATORY TEST; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; PREVALENCE; QUALITY CONTROL; RETROSPECTIVE STUDY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTITUBERCULAR AGENTS; CHILD; CHILD, PRESCHOOL; CHINA; DRUG RESISTANCE, MULTIPLE, BACTERIAL; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; FEMALE; HUMANS; INFANT; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; PREVALENCE; TUBERCULOSIS, MULTIDRUG-RESISTANT; TUBERCULOSIS, PULMONARY; YOUNG ADULT;

EID: 79952333978     PISSN: 10806040     EISSN: 10806059     Source Type: Journal    
DOI: 10.3201/eid1703.100812     Document Type: Article

References (10)

1. Wright A, Zignol M, Van Deun A, Falzon D, Gerdes SR, Feldman K, et al. Epidemiology of antituberculosis drug resistance 2002-07: an updated analysis of the Global Project on Anti-Tuberculosis Drug Resistance Surveillance. Lancet. 2009; 373: 1861-73. DOI: 10.1016/ S0140-6736(09)60331-7
2. World Health Organization. Countries that had reported at least one XDR-TB case by Sept. 2009 [cited 2010 Mar 15]. http://www.who. int/tb/challenges/xdr/xdr_map_sep09.pdf
3. Raviglione MC, Smith IM. XDR tuberculosis-implications for global public health. N Engl J Med. 2007;356:656-9. DOI: 10.1056/ NEJMp068273
4. Shah NS, Wright A, Bai GH, Barrera L, Boulahbal F, Martín-Casabona N, et al. Worldwide emergence of extensively drug-resistant tuberculosis. Emerg Infect Dis. 2007;13:380-7. DOI: 10.3201/ eid1303.061400
5. Chinese Medical Association. Clinical techniques standard operating procedures. Tuberculosis section. Beijing: People's Military Medical Press; 2004.
6. World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis. WHO/HTM/TB/2006.361. Geneva: The Organization; 2006.
7. Sun Z, Chao Y, Zhang X, Zhang J, Li Y, Qiu Y, et al. Characterization of extensively drug-resistant Mycobacterium tuberculosis clinical isolates in China. J Clin Microbiol. 2008;46:4075-7. DOI: 10.1128/JCM.00822-08
8. Zhao M, Li X, Xu P, Shen X, Gui X, Wang L, et al. Transmission of MDR and XDR tuberculosis in Shanghai, China. PLoS ONE. 2009;4:e4370. DOI: 10.1371/journal.pone.0004370
9. Kim SJ. Is second-line anti-tuberculosis drug susceptibility testing reliable? Int J Tuberc Lung Dis. 2004;8:1157-8.
10. Kim SJ. Drug-susceptibility testing in tuberculosis: methods and reliability of results. Eur Respir J. 2005;25:564-9. DOI: 10.1183/09031936.05.00111304